新型TK抑制剂达克替尼在肺腺癌细胞增殖和凋亡的影响
Effect of a Novel TK Inhibitor Dacomitinib on Proliferation and Apoptosis of Lung Adenocarcinoma Cells
DOI: 10.12677/HJMCe.2021.93014, PDF,   
作者: 郭李玲：甘肃医学院附属医院全科医学科，甘肃 平凉；毛 俊：甘肃医学院基础医学院生物化学与分子生物学，甘肃 平凉
关键词: 达克替尼；肺腺癌；增殖；凋亡；Dacomitinib； Lung Adenocarcinoma； Proliferation； Apoptosis
摘要: 目的：探究新型TK抑制剂达克替尼对人肺腺癌A549细胞增殖与侵袭作用及机制。方法：人肺腺癌A549细胞为研究对象，根据预实验结果，将人肺腺癌细胞系A549分成3组，即空白对照组，低剂量组和高剂量组。RT-PCR检测EFGR和凋亡蛋白Caspase-3和Caspase-9的表达，流式细胞仪检测细胞的分裂周期和细胞凋亡率，CCK-8检测细胞的增殖。结果：空白对照组，低剂量组和高剂量组的EFGR，Caspase-3和Caspase-9 mRNA相对表达量相对量比较具有统计学差异(P < 0.05)；空白对照组的EFGR mRNA相对表达量相对量要明显高于低剂量组和高剂量组(P < 0.05)，空白对照组的Caspase-3和Caspase-9 mRNA相对表达量要明显低于低剂量组和高剂量组(P < 0.05)，低剂量组和高剂量组的EFGR，Caspase-3和Caspase-9 mRNA相对表达量相对量比较无统计学差异(P > 0.05)。低剂量组和高剂量组的G0/G1期比例明显高于空白对照组(P < 0.05)；S期和G2期比例明显低于空白对照组(P < 0.05)。低剂量组和高剂量组的总凋亡率明显高于空白对照组(P < 0.05)；高剂量组晚期凋亡率明显高于低剂量组(P < 0.05)。药物处理2天后，空白对照组的细胞增值率要明显高于低剂量组和高剂量组(P < 0.05)；药物处理3天后，空白对照组的细胞增值率要明显高于低剂量组和高剂量组(P < 0.05)。结论：低剂量达克替尼可以抑制肺腺癌细胞的增殖，促进肺腺癌细胞的凋亡，并且可以抑制EFGR的表达，可以作为耐药性肺腺癌的治疗方案。
Abstract: Objective: The objective is to investigate the proliferation and invasion of human lung adenocar-cinoma A549 cells induced by a novel TK inhibitor, dacomitinib, and its mechanism. Methods: Human lung adenocarcinoma cell line A549 was divided into three groups according to the pre-liminary results, namely the blank control group, the low-dose group and the high-dose group. The expression of EFGR and Caspase-3 and Caspase-9 was detected by RT-PCR. The cycle of cell division and apoptotic rate of the cell were detected by flow cytometry. The cell proliferation was detected by CCK-8. Results: The relative expressions of EFGR, caspase-3 and caspase-9 mRNA in blank control group, low-dose group and high-dose group were statistically different (P < 0.05). The relative expression of EFGR mRNA in the blank control group was significantly higher than that in the low-dose group and the high-dose group (P < 0.05). The relative expression of Caspase-3 and caspase-9 mRNA in the blank control group was significantly lower than that in the low-dose group and high-dose group (P < 0.05). There was no significant difference in the relative expression of EFGR, caspase-3 and caspase-9 mRNA between the low-dose group and the high-dose group (P > 0.05). The proportions of G0/G1 phase in low-dose group and high-dose group were significantly higher than those in blank control group (P < 0.05), while the proportions of S phase and G2 phase were significantly lower than those in blank control group (P < 0.05). The total apoptotic rate of the low-dose group and the high-dose group significantly higher than that of the blank control group (P < 0.05), and the late apoptotic rate of the high-dose group was significantly higher than that of the low-dose group (P < 0.05). After 2 days of drug treatment, the cell increment rate of blank control group was significantly higher than that of low-dose group and high-dose group (P < 0.05); after 3 days of drug treatment, the cell increment rate of blank control group was significantly higher than that of low-dose group and high-dose group (P < 0.05). Conclusion: Low-dose of dacomitinib can inhibit the proliferation of lung adenocarcinoma cells, promote the apoptosis of lung adenocarcinoma cells, and inhibit the expression of EFGR. It can be used as a therapeutic regimen for drug-resistant lung adenocarcinoma.Objective: The objective is to investigate the proliferation and invasion of human lung adenocarci-noma A549 cells induced by a novel TK inhibitor, dacomitinib, and its mechanism. Methods: Human lung adenocarcinoma cell line A549 was divided into three groups according to the preliminary re-sults, namely the blank control group, the low-dose group and the high-dose group. The expression of EFGR and Caspase-3 and Caspase-9 was detected by RT-PCR. The cycle of cell division and apop-totic rate of the cell were detected by flow cytometry. The cell proliferation was detected by CCK-8. Results: The relative expressions of EFGR, caspase-3 and caspase-9 mRNA in blank control group, low-dose group and high-dose group were statistically different (P < 0.05). The relative expression of EFGR mRNA in the blank control group was significantly higher than that in the low-dose group and the high-dose group (P < 0.05). The relative expression of Caspase-3 and caspase-9 mRNA in the blank control group was significantly lower than that in the low-dose group and high-dose group (P < 0.05). There was no significant difference in the relative expression of EFGR, caspase-3 and caspa-se-9 mRNA between the low-dose group and the high-dose group (P > 0.05). The proportions of G0/G1 phase in low-dose group and high-dose group were significantly higher than those in blank control group (P < 0.05), while the proportions of S phase and G2 phase were significantly lower than those in blank control group (P < 0.05). The total apoptotic rate of the low-dose group and the high-dose group significantly higher than that of the blank control group (P < 0.05), and the late apoptotic rate of the high-dose group was significantly higher than that of the low-dose group (P < 0.05). After 2 days of drug treatment, the cell increment rate of blank control group was signifi-cantly higher than that of low-dose group and high-dose group (P < 0.05); after 3 days of drug treatment, the cell increment rate of blank control group was significantly higher than that of low-dose group and high-dose group (P < 0.05). Conclusion: Low-dose of dacomitinib can inhibit the proliferation of lung adenocarcinoma cells, promote the apoptosis of lung adenocarcinoma cells, and inhibit the expression of EFGR. It can be used as a therapeutic regimen for drug-resistant lung ade-nocarcinoma.
文章引用：郭李玲, 毛俊. 新型TK抑制剂达克替尼在肺腺癌细胞增殖和凋亡的影响[J]. 药物化学, 2021, 9(3): 112-118. https://doi.org/10.12677/HJMCe.2021.93014

参考文献

[1] Jordan, E.J., Kim, H.R., Arcila, M.E., et al. (2017) Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 7, 15 p. [Google Scholar] [CrossRef] 
[2] Velcheti, V., Hida, T., Reckamp, K.L., et al. (2017) Phase 2 Study of Lenvatinib in Patients with RET Fusion-Positive Adenocarcinoma of the Lung. European Journal of Cancer, 72, S178. [Google Scholar] [CrossRef] 
[3] Feng, M., Zhu, J., Liang, L., et al. (2017) Diagnostic Value of Tumor Markers for Lung Adenocarcinoma-Associated Malignant Pleural Effusion: A Validation Study and Me-ta-Analysis. International Journal of Clinical Oncology, 22, 283-290. [Google Scholar] [CrossRef] [PubMed]
[4] Ono, A., Kenmotsu, H., Watanabe, M., et al. (2014) Mutant Al-lele Frequency Predicts the Efficacy of EGFR-TKIs in Lung Adenocarcinoma Harboring the L858R Mutation. Annals of Oncology, 25, 1948-1953. [Google Scholar] [CrossRef] [PubMed]
[5] Kim, I.A., Lee, J.S., Kim, H.J., et al. (2018) Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs: A Retrospective Study. BMC Cancer, 18, Article No. 768. [Google Scholar] [CrossRef] [PubMed]
[6] Zhou, F., Ma, W., Li, W., et al. (2018) Thick-Wall Cavity Predicts Worse Progression-Free Survival in Lung Adenocarcinoma Treated with First-Line EGFR-TKIs. BMC Cancer, 18, Article No. 1033. [Google Scholar] [CrossRef] [PubMed]
[7] Chen, H., Yang, X., Liu, H., et al. (2017) Correlation between Serum Tumor Markers and Efficacy of First-Line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma. Chi-nese Journal of Lung Cancer, 1, 76-87.
[8] Ma, X., Zhu, H., Guo, H., et al. (2016) Risk Factors of Brain Metastasis during the Course of EGFR-TKIs Therapy for Patients with EGFR-Mutated Advanced Lung Adenocarcinoma. Onco-target, 7, 81906-81917. [Google Scholar] [CrossRef] [PubMed]
[9] Ming-Szu, H., Jr-Hau, L., Lin, Y.C., et al. (2016) The Content of Mutant EGFR DNA Correlates with Response to EGFR-TKIs in Lung Adenocarcinoma Patients with Common EGFR Mutations. Medicine, 95, e3991. [Google Scholar] [CrossRef] 
[10] 周玮玮, 王磊, 苗玉, 等. 量子点荧光探针检测肺腺癌组织中EGFR的表达[J]. 标记免疫分析与临床, 2018, 25(5): 736-739.
[11] 史张, 宋长恩, 施睿峰, 等. 肺腺癌CT及临床特征与EGFR 19号外显子突变的相关性研究[J]. 临床放射学杂志, 2017, 36(4): 490-494.
[12] Bose, T.O., Pham, Q.M., Jellison, E.R., et al. (2013) CD11a Regulates Effector CD8 T Cell Differentiation and Central Memory Development in Response to Infection with Listeria Monocytogenes. Infection and Immunity, 81, 1140-1151. [Google Scholar] [CrossRef] 
[13] Tai, W., Chen, Z. and Cheng, K. (2013) Expression Profile and Func-tional Activity of Peptide Transporters in Prostate Cancer Cells. Molecular Pharmaceutics, 10, 477-487. [Google Scholar] [CrossRef] [PubMed]
[14] Ferrone, S. and Marincola, F.M. (1995) Loss of HLA Class I Antigens by Melanoma Cells: Molecular Mechanisms, Functional Significance and Clinical Relevance. Immunology Today, 16, 487-494. [Google Scholar] [CrossRef] [PubMed]